Premium
Side‐effects and Placental Function in Six Pregnant Women Treated with Ferastral®
Author(s) -
Svanberg B.,
Rybo G.
Publication year - 1977
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1977.tb01265.x
Subject(s) - medicine , pregnancy , apgar score , placenta , renal function , side effect (computer science) , physiology , liver function , excretion , liver function tests , obstetrics , fetus , biology , programming language , genetics , computer science
A pilot study has been carried out with a new parenteral iron preparation, Ferastral®, in six pregnant women who had previously experienced side‐effects to oral iron. Patients were selected with only marginal anaemia and whose Hb‐concentration (10.3–12.4 g/100 ml) could be considered to be in the low normal range for pregnancy. Each patient received a total dose of 500 mg Ferastral, by the intramuscular route, but the single doses and times administration varied. In the study special attention was given to kidney and liver function, to placental function, and to side‐effects. At birth the infants were assessed by the Apgar score, and the placentae were examined both microscopically and macroscopically. At the initial Hb‐levels chosen and the Ferastral dose used, no significant changes were observed in Hb‐concentrations. Ferastral did not affect the values of the laboratory parameters of liver and kidney function studied. Placental function was unaffected, as shown by all oestrogen excretion values remaining within the normal range and the amount of estrogens increasing as expected as pregnancy progressed. Careful histological study showed no placental changes which could be related to Ferastral. In none of the infants were the Apgar scores less than 8. Concerning side‐effects, pain and discolouration at the site of the injection were observed in some cases.